SCHEMBL5753622

SCHEMBL5753622

COc1ccc(S(=O)(=O)N2CCN(C(C)c3nc(C(C(c4nc(C(C)N5CCN(S(=O)(=O)c6ccc(OC)cc6)CC5)nc5ccccc45)N(C)C4OCCO4)N(C)C4OCCO4)c4ccccc4n3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.61
GBA1 P04062 5/20 0.45
HSD11B1 P28845 1/20 0.44
PKM P14618 4/20 0.43
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.40
PKLR P30613 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCR6 P51684 1/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3816483 0.84 CFTR (0.70) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL13723633 0.82 CFTR (0.60) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL3818773 0.81 CFTR (0.68) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL3824104 0.80 CFTR (0.80) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL3824055 0.79 CFTR (0.70) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL3820105 0.78 CFTR (0.62) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL15457219 0.78 CFTR (0.64) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL15457303 0.78 CFTR (0.68) CFTRGBA1HSD11B1PKMALDH1A1
Ammonia Solution, Strong SCHEMBL6341356 0.78 CFTR (0.61) CFTRGBA1HSD11B1PKMALDH1A1
SCHEMBL3823079 0.78 CFTR (0.76) CFTRGBA1HSD11B1PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 CFTR 1/4885GBA1 575/4885HSD11B1 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.